J&J shareholding in Biocartis decreases

Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday.

In a disclosure of a transparency notification, Biocartis said that shareholding of Johnson & Johnson Innovation (JJDC, Inc.), has decreased below the 15% notification threshold. This  concerns a passive downward crossing of the 15% notification threshold as a result of Biocartis’ recent successful equity placement of €32.7m.

Johnson & Johnson Innovation – JJDC, Inc. now holds 13.68% of the Biocartis’ shares, and 6,107,518 voting securities.